US national stem cell research hub to reassess role after director quits

By Zachary Brennan

- Last updated on GMT

Related tags Stem cell

(Picture credit Flickr/Joseph Elshernd)
(Picture credit Flickr/Joseph Elshernd)
Despite the director’s resignation, the US NIH Intramural Center for Regenerative Medicine (CRM) has not closed and will hold a workshop to guide the direction of the center’s future, the NIH told us.  

This is a fast evolving area of science and NIH decided to step back and reassess what the field needs in 2014 and beyond and where NIH can have the greatest impact​,” spokeswoman Renate Myles told

The agency will hold a workshop tentatively scheduled for May 5 “that will convene a group of experts in the field to address current obstacles to translation of cell therapies and will help prioritize a number of requirements that the larger community has articulated through white papers over the past two years​,” she said. “NIH will consider the feedback from the workshop and establish a set of goals for the CRM​.”

Rao’s Departure

The revelations come as the program’s director, stem cell biologist Mahendra Rao, left the NIH on March 28, according to media reports​.

With a budget of $52m over seven years, the CRM was established in 2010 to centralize the NIH’s stem cell work and to develop therapies from induced pluripotent stem (iPS) cells, which are adult cells converted into embryonic-like stem cells.

Researchers from the center have since generated more than 400 lines of iPS cells, and funded two contracts, including one for Lonza​, to create 12 lines of clinical-grade iPS cells that will be available later this year.

If you look specifically at the NIH contract where we are to produce a clinical grade (GMP) iPSC master cell bank, at this point our engineering runs are complete​,” Don Kovarcik, business development manager at Lonza, told us.

 iPSC trial

The CRM has only approved one application for a clinical trial, which was made by Kapil Bharti of the National Eye Institute. The team aims to use iPS cells to treat age-related macular degeneration of the retina, and hopes to commence human trials within a few years.

Rao took the helm in 2011, and according to the report from Nature, relations between he and NIH seem to have soured after the agency only awarded funding to one project aiming to move iPS cells into a clinical trial. Rao says he resigned after this became clear and said he hoped for five trials to be funded.

Related topics Markets & Regulations Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more